Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Closes Offering of $275M in Senior Convertible Notes

NEW YORK (GenomeWeb News) – Affymetrix has closed its registered offering of $275 million of senior convertible notes.
 
The company said it plans to use the funds from the sale of the unsecured, 3.5 percent notes for working capital and for general corporate purposes, which may include funding operations, acquisitions, and capital expenditures.
 
The notes will be convertible into Affymetrix common stock at a rate of 33.191 shares per $1,000 principal amount of notes, which it said is equivalent to around $30.12 a share.
 
That value represents a 39 percent premium over the firm’s closing stock price on Nov. 13, the day the offering was announced.
 

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.